Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients
Status:
Withdrawn
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Many patients with eczema (atopic dermatitis) have an inherent defect in their skin barrier
as demonstrated by high water loss. In laboratory conditions, studies have shown that
pioglitazone restores the skin barrier function in skin from eczema patients. The purpose of
this study is to determine if taking pioglitazone improves the skin barrier function in
people with eczema.
Phase:
N/A
Details
Lead Sponsor:
University of Rochester
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)